Humacyte, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Humacyte, Inc. (HUMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.23 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.03M shares, a 34.32% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 204.10K shares, a 96.32% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 2.67M shares, a 1763.02% increase year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 18.50K shares, a 94.09% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 9.81M shares, a 497.94% increase from fiscal 2024.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.64M shares, a 71.47% decline from fiscal 2023.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.75M shares, a 106.05% increase from fiscal 2022.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.79M shares, a 24.01% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.03M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 1.23M shares 10-Q · filed 2026-08-12 | 3.91M shares derived: sum of 3 quarters · filed 2026-08-12 | 3.93M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 204.10K shares 10-Q · filed 2026-05-13 | 2.88M shares derived: sum of 2 quarters · filed 2026-05-13 | 2.90M shares derived: sum of 3 quarters · filed 2026-05-13 | 4.46M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 2.67M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 2.69M shares derived: sum of 2 quarters · filed 2026-03-27 | 4.26M shares derived: sum of 3 quarters · filed 2026-03-27 | 9.81M shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 18.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.59M shares derived: sum of 2 quarters · filed 2025-11-12 | 7.14M shares 10-Q · filed 2025-11-12 | 7.28M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.57M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 7.12M shares 10-Q · filed 2025-08-11 | 7.26M shares derived: sum of 3 quarters · filed 2025-08-11 | 7.58M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 5.55M shares 10-Q · filed 2025-05-13 | 5.70M shares derived: sum of 2 quarters · filed 2025-05-13 | 6.01M shares derived: sum of 3 quarters · filed 2025-05-13 | 7.04M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 143.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 456.35K shares derived: sum of 2 quarters · filed 2025-03-31 | 1.48M shares derived: sum of 3 quarters · filed 2025-03-31 | 1.64M shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 312.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 1.34M shares derived: sum of 2 quarters · filed 2024-11-08 | 1.50M shares 10-Q · filed 2024-11-08 | 6.68M shares derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | 1.03M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 1.18M shares 10-Q · filed 2024-08-13 | 6.37M shares derived: sum of 3 quarters · filed 2024-08-13 | 6.50M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 157.65K shares 10-Q · filed 2024-05-13 | 5.34M shares derived: sum of 2 quarters · filed 2024-05-13 | 5.47M shares derived: sum of 3 quarters · filed 2024-05-13 | 5.77M shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 5.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 5.31M shares derived: sum of 2 quarters · filed 2024-03-28 | 5.62M shares derived: sum of 3 quarters · filed 2024-03-28 | 5.75M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 127.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 429.95K shares derived: sum of 2 quarters · filed 2023-11-09 | 564.15K shares 10-Q · filed 2023-11-09 | 2.68M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 302.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 436.75K shares 10-Q · filed 2023-08-14 | 2.55M shares derived: sum of 3 quarters · filed 2023-08-14 | 2.80M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 134.20K shares 10-Q · filed 2023-05-12 | 2.25M shares derived: sum of 2 quarters · filed 2023-05-12 | 2.49M shares derived: sum of 3 quarters · filed 2023-05-12 | 2.81M shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 2.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 2.36M shares derived: sum of 2 quarters · filed 2023-03-24 | 2.68M shares derived: sum of 3 quarters · filed 2023-03-24 | 2.79M shares 10-K · filed 2023-03-24 |
| 2022-09-30 | 242.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 561.38K shares derived: sum of 2 quarters · filed 2022-11-10 | 675.08K shares 10-Q · filed 2022-11-10 | 1.09M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 318.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 432.58K shares 10-Q · filed 2022-08-12 | 845.16K shares derived: sum of 3 quarters · filed 2022-08-12 | |
| 2022-03-31 | 113.70K shares 10-Q · filed 2022-05-13 | 526.29K shares derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | 412.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 2.25M shares 10-K · filed 2022-03-29 | ||
| 2021-09-30 | 1.84M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |